Anti-VEGF Receptor 1 antibody [Y103] (Ab32152)
FLT, FRT, VEGFR1, FLT1, Vascular endothelial growth factor receptor 1, VEGFR-1, Fms-like tyrosine kinase 1, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor, FLT-1
详细信息
特异性
Based on our results, no splice isoforms can be detected.
背景信息
Product Specifications Anti-VEGF Receptor 1 antibody [Y103] (ab32152) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-P, IP, WB in hamster, human, mouse, rat samples. Anti-VEGF Receptor 1 antibody [Y103] (ab32152) specifically detects VEGF Receptor 1 (UniProt ID: P17948; Molecular weight: 148kDa) and is sold in 100 µL and 1 mL selling sizes. Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-VEGF Receptor 1 antibody [Y103] (ab32152) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-VEGF Receptor 1 antibody [Y103] (ab32152) has been cited over 308 times in peer reviewed journals and is trusted by the scientific community. Anti-VEGF Receptor 1 antibody [Y103] (ab32152) has 21 independent reviews from customers. Related Products Antibody clone Y103 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 488, Alexa Fluor® 555, Alexa Fluor® 647, Alexa Fluor® 594, Alexa Fluor® 568, Alexa Fluor® 750 ( ab309078, ab309079, ab309080, ab311783, ab313064, ab321585 ). Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (292)
Reconstructing the ischemic osteogenic microenvironment through hierarchical scaffolds orchestrating Mg(2+) signaling and neuropilin-1-mediated angiogenesis.
通过分级支架重建缺血性成骨微环境,协调Mg(2+)信号传导和神经纤毛蛋白-1介导的血管生成。
Ultrasound-Boosted Liposomal Prodrug Overcomes Age-Associated Biodistribution Disparity in Pediatric Solid Tumor Therapy.
超声增强脂质体前药克服了儿童实体瘤治疗中与年龄相关的生物分布差异。
N6-Methyladenosine Modification of circIST1 Promotes Hypoxia-Inducible Factor α-mediated Glycolysis and Progression in Hepatocellular Carcinoma.
circIST1 的 N6-甲基腺苷修饰促进缺氧诱导因子α介导的糖酵解和肝细胞癌的进展。
Taohong Siwu Decoction Regulates MSC-Mediated H-Type Angiogenesis to Accelerate Bone Fracture Healing Through VHL/HIF-1α Ubiquitination.
桃红四物汤通过VHL/HIF-1α泛素化调节MSC介导的H型血管生成,从而加速骨折愈合。
Aryl Hydrocarbon Receptor (AhR) and Vascular Endothelial Growth Factor (VEGF) Crosstalk in Doxorubicin Nephrotoxicity: Mechanisms and Therapeutic Perspectives.
阿霉素肾毒性中芳烃受体(AhR)和血管内皮生长因子(VEGF)的相互作用:机制和治疗前景。
Modulation of breast cancer progression in high-altitude hypoxia by Tongqiaohuoxue Decoction via HIF-1α/VEGF signaling.
通桥活血汤通过 HIF-1α/VEGF 信号通路调节高海拔缺氧条件下乳腺癌的进展。
Trace element-dictated exosome modules and self-adaptive dual-network hydrogel orchestrate diabetic foot regeneration through complement-mitochondria-autophagy circuitry.
微量元素决定的外泌体模块和自适应双网络水凝胶通过补体-线粒体-自噬回路协调糖尿病足再生。
Covalently reactive microparticles imbibe blood to form fortified clots for rapid hemostasis and prevention of rebleeding.
共价反应微粒吸收血液形成强化血凝块,从而快速止血并防止再次出血
pH-responsive bilayer hydrogel with sequential release of morin-based nanoparticles and bFGF for the treatment of the "ice and fire" wounds.
用于治疗“冰火”伤口的 pH 响应型双层水凝胶,可依次释放莫林基纳米颗粒和 bFGF。
Decoy-PROTAC for specific degradation of "Undruggable" STAT3 transcription factor.
诱饵-PROTAC 可特异性降解“不可成药”的 STAT3 转录因子
- 1
- 2
- 3
- 4
- 5
- 6
- 30